Therapy News and Research

RSS

Acorda Therapeutics receives marketing approval from FDA for AMPYRA

Acorda Therapeutics, Inc. today announced that it has received marketing approval from the U.S. Food and Drug Administration (FDA) for AMPYRA™ (dalfampridine), an oral treatment to improve walking in patients with multiple sclerosis (MS).

22 Jan 2010

California Heart Center joins Cedars-Sinai Heart Institute and Cedars-Sinai Medical Care Foundation

The California Heart Center, the cardiology group that developed the nation's largest heart transplant program, has joined the Cedars-Sinai Heart Institute and Cedars-Sinai Medical Care Foundation.

22 Jan 2010

ACS Chemical Biology report supports zebrafish for drug development

By combining the tools of medicinal chemistry and zebrafish biology, a team of Vanderbilt investigators has identified compounds that may offer therapeutic leads for bone-related diseases and cancer.

22 Jan 2010

Focused Ultrasound Surgery Foundation disbursed $1 million in research awards; looks forward to fund more projects in 2010

The Focused Ultrasound Surgery Foundation has disbursed nearly $1 million in research awards for work on a breakthrough medical technology and is making more project funding available in 2010.

22 Jan 2010

Pennsylvania Department of Health offers smokers free NRT kits as part of 'Determined To Quit' Week

The Department of Health will provide free nicotine patches to help Pennsylvanians who are trying to quit tobacco starting Monday, Jan. 25. Kits will be offered -- while supplies last -- through the PA Free Quitline at 1-800-QUIT-NOW.

22 Jan 2010

Researchers discover genetic variations that predict clinical outcomes in patients with stomach cancer

Researchers at the University of Southern California (USC) have, for the first time, identified specific genetic variations that predict clinical outcomes in patients with gastric (stomach) cancer.

22 Jan 2010

Fluctuation in insulin delivery due to pump movement may increase risk of complications in diabetics

Researchers at Sansum Diabetes Research Institute and University of California, Santa Barbara have concluded that changing the height of a conventional insulin pump in relation to its tubing and infusion set can significantly impact expected insulin delivery rates. Such changes can occur during routine daily activities like dressing, sleeping or showering.

22 Jan 2010

CytRx announces its plans to advance multiple oncology development programs in 2010

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced its plans for 2010 aimed at advancing the clinical development of its high-value drug development pipeline and enhancing shareholder value.

22 Jan 2010

Researchers identify new therapeutic approach for stroke treatment

For the first time, research led by Youming Lu, PhD, MD, Professor of Neurology and Neuroscience at LSU Health Sciences Center New Orleans School of Medicine, has identified a novel mechanism that may trigger brain damage during stroke and identified a therapeutic approach to block it.

22 Jan 2010

New study concerning the severity of H1N1 influenza published in CMAJ

A new study published in CMAJ (Canadian Medical Association Journal) http://www.cmaj.ca/cgi/doi/10.1503/cmaj.091884 concerning the severity of H1N1 influenza has found that admissions to an intensive care unit (ICU) were associated with a longer interval between symptom onset and treatment with antivirals and with presence of an underlying medical condition.

22 Jan 2010

CMO to manufacture Gaia BioPharma's GAI-122 Mitochondria-targeted neuroprotective agent

AlphaRx Inc. announced today that its licensee, Gaia BioPharma Limited, has signed an agreement with a contract manufacturing organization (CMO), to manufacture GAI-122 for use in the planned Phase I and II clinical trials of that product candidate. GAI-122 is being developed as I.V. administered formulation of an intracellular neuroprotectant that employs AlphaRx's proprietary nano-emulsion formulation technology.

22 Jan 2010

AKD Global announces new class of cancer treatments in development

AKD Global announced today the discovery of a new class of cancer treatments in development, providing hope for millions of sufferers. The spectacular results demonstrate a highly potent effect on cancer cells with no toxicity to healthy tissue. AKD is raising funds to continue development.

22 Jan 2010

Controversy around Merck's pricing for its AIDS drug Isentress

The controversy around Merck and Co. Pharmaceuticals’ pricing for its key AIDS drug Isentress — at nearly $13,000 per patient yearly, the most expensive first line AIDS therapy on the US market today — continued this week following Merck’s reaction to recent public criticism of its AIDS drug pricing. Merck ramped up its damage control PR efforts, issuing a press release that sought to rewrite the history of Isentress and deflect attention by claiming AIDS Healthcare Foundation has been unfairly attacking them.

22 Jan 2010

Panel discussion on benefits of oral chemotherapy in cancer care

US Oncology, Inc. partnered with the Association of Community Cancer Centers, Association of Oncology Social Work, American Society for Clinical Oncology, Community Oncology Alliance, Oncology Nursing Society and the National Patient Advocate Foundation in hosting a panel discussion on Capitol Hill today to examine the benefits of oral chemotherapy in cancer care, as well as challenges in its prescribing, accessibility and adherence in the current health care system.

22 Jan 2010

New learning centre dedicated to train CT health care specialists established

The Michener Institute for Applied Health Sciences and GE Healthcare Canada today announced the establishment of a new learning centre dedicated to training both the current and next generation of CT health care specialists.

22 Jan 2010

Australian scientists discover cells that cause a common type of childhood leukaemia

Scientists at The Royal Melbourne Hospital and the University of Melbourne in Australia have discovered the cells that cause a common type of childhood leukaemia - T cell Acute Lymphoblastic Leukaemia (T-ALL). Targeting of these cells may lead to improved treatments for this disease and help prevent relapse.

22 Jan 2010

Findings may aid in developing therapeutic drugs for stroke and other neurodegenerative diseases

Biomedical scientists from the University of Central Florida and Louisiana State University have identified a way to block a "cell death signal" that they believe triggers brain damage during strokes.

22 Jan 2010

Genzyme receives PDUFA date from FDA for its Biologics License Application for Lumizyme

Genzyme Corporation announced today that it has received a June 17, 2010 PDUFA date from the FDA for its Biologics License Application for Lumizyme™ (alglucosidase alfa) seeking approval for the therapy produced at the 4000 L scale.

21 Jan 2010

Behavioral Innovations opens its first autism treatment center in Texas

Behavioral Innovations, the premier provider of Applied Behavior Analysis (ABA) services for families of children with autism and other developmental disorders, today announces the opening of its San Antonio location, which will begin offering services February 1. The company is in the process of expanding to Fort Worth and Wichita Falls where they will begin serving families in early spring.

21 Jan 2010

FDA approves continuous-flow heart-assist device pioneered at Texas Heart Institute at SLEH

The federal Food and Drug Administration today approved a continuous-flow heart-assist device pioneered at the Texas Heart Institute (THI) at St. Luke’s Episcopal Hospital (SLEH) for use as a permanent treatment for advanced heart failure.

21 Jan 2010

Therapy News and Research

Acorda Therapeutics receives marketing approval from FDA for AMPYRA

California Heart Center joins Cedars-Sinai Heart Institute and Cedars-Sinai Medical Care Foundation

ACS Chemical Biology report supports zebrafish for drug development

Focused Ultrasound Surgery Foundation disbursed $1 million in research awards; looks forward to fund more projects in 2010

Pennsylvania Department of Health offers smokers free NRT kits as part of 'Determined To Quit' Week

Researchers discover genetic variations that predict clinical outcomes in patients with stomach cancer

Fluctuation in insulin delivery due to pump movement may increase risk of complications in diabetics

CytRx announces its plans to advance multiple oncology development programs in 2010

Researchers identify new therapeutic approach for stroke treatment

New study concerning the severity of H1N1 influenza published in CMAJ

CMO to manufacture Gaia BioPharma's GAI-122 Mitochondria-targeted neuroprotective agent

AKD Global announces new class of cancer treatments in development

Controversy around Merck's pricing for its AIDS drug Isentress

Panel discussion on benefits of oral chemotherapy in cancer care

New learning centre dedicated to train CT health care specialists established

Australian scientists discover cells that cause a common type of childhood leukaemia

Findings may aid in developing therapeutic drugs for stroke and other neurodegenerative diseases

Genzyme receives PDUFA date from FDA for its Biologics License Application for Lumizyme

Behavioral Innovations opens its first autism treatment center in Texas

FDA approves continuous-flow heart-assist device pioneered at Texas Heart Institute at SLEH

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News